Search by ticker code:
Generic filters

Search by ticker code:
Generic filters

Search by ticker code:
Generic filters

Why CSL Limited (ASX:CSL) shares are a hold for me

CSL Limited (ASX: CSL) has continued to be in the top 20 traded shares on the ASX recently.

Mixed announcements have resulted in a volatile share price, with the latest announcement causing the CSL share price to rally on the back of COVID-19 vaccine plans.

CSL shares are trading at $296 at the time of writing.

CSL share price chart

Source: CSL 3-month share price chart

For an ASX share that is meant to be one of the more defensive picks, CSL has had a volatile journey this year. Initially, worldwide lockdowns threatened to significantly impact blood collection volumes, especially in the US.

There was then some optimism when CSL announced last month it had signed two deals for two separate COVID-19 vaccines. Despite this result, the market found this difficult to price in and the CSL share price remained relatively flat.

The most recent announcement has been good news, but I have some concerns towards the macroeconomic environment that CSL operates within.

What’s caused the recent CSL share price volatility?

Despite strong FY20 results, increasing pressure from competition is now a significant risk facing CSL’s market share.

CSL’s immunoglobulin therapies make up 40% of revenues. Now with rivals such as Roche, Sanofi and Takeda approaching commercialisation with similar therapies, some analysts are saying that CSL may have to increase spending in research and development in order to stay ahead of the competition.

This is interesting because last year, CSL CEO Paul Perreault actually challenged its rivals such as Takeda to “step up” or risk demand greatly outstripping supply in the global immunoglobulin market.

It seems healthy competition in this industry is ideal from an ethical standpoint, as supply can be matched to meet global demand. However, financially this is less than ideal because while some have pointed out that CSL has enjoyed a monopoly in the past, increased competition can only bring market share down, which hurts financial performance.

I don’t doubt that CSL would be a strong, defensive, dividend-paying share that’d still perform quite well in the long-term. However, I’m really interested in companies that still have a large runway for growth and aren’t under as much pressure from competition.

Why I prefer Xero shares

I recently wrote an article on Xero Limited (ASX: XRO), which explains why I think it could be a further wealth winner. Xero doesn’t have a monopoly, which means it can still expand into new markets and not be brought down by the competition as much as in a monopolistic situation.

Xero is well-established in Australia but has only tapped into 20% of the total addressable market in overseas regions. This remaining 80% represents the growth runway I mentioned earlier.

Xero has had a great track record of growing the business and showing disciplined cost management. The cost structure scales extremely well as the business increases its revenues.

Maybe I’m biased towards software-as-a-service (SaaS) businesses, but CSL is a hold for me currently.

$50,000 per year in passive income from shares? Yes, please!

With interest rates UP, now could be one of the best times to start earning passive income from a portfolio. Imagine earning 4%, 5% — or more — in dividend passive income from the best shares, LICs, or ETFs… it’s like magic.

So how do the best investors do it?

Chief Investment Officer Owen Rask has just released his brand new passive income report. Owen has outlined 10 of his favourite ETFs and shares to watch, his rules for passive income investing, why he would buy ETFs before LICs and more.

You can INSTANTLY access Owen’s report — or get it emailed to you — for FREE by CLICKING HERE NOW or the button below.

Unsubscribe anytime. Read our TermsFinancial Services GuidePrivacy Policy. We’ll never sell your email address. Our company is Australian owned.

Information warning: The information on this website is published by The Rask Group Pty Ltd (ABN: 36 622 810 995) is limited to factual information or (at most) general financial advice only. That means, the information and advice does not take into account your objectives, financial situation or needs. It is not specific to you, your needs, goals or objectives. Because of that, you should consider if the advice is appropriate to you and your needs, before acting on the information. If you don’t know what your needs are, you should consult a trusted and licensed financial adviser who can provide you with personal financial product advice. In addition, you should obtain and read the product disclosure statement (PDS) before making a decision to acquire a financial product. Please read our Terms and Conditions and Financial Services Guide before using this website. The Rask Group Pty Ltd is a Corporate Authorised Representative (#1280930) of AFSL #383169.

At the time of publishing, Patrick owns shares in Xero Limited.
Skip to content